Stockscreener 앱 받기
6.00
1.52%
0.09
시간 외 거래:
6.00
전일 마감가:
$5.91
열려 있는:
$5.86
하루 거래량:
517.76K
Relative Volume:
0.98
시가총액:
$478.03M
수익:
$351.37M
순이익/손실:
$-158.35M
주가수익비율:
-3.0733
EPS:
-1.9523
순현금흐름:
$-132.03M
1주 성능:
-1.64%
1개월 성능:
+26.58%
6개월 성능:
+108.33%
1년 성능:
+89.27%
1일 변동 폭
$5.85
$6.07
1주일 범위
$5.79
$6.185
52주 변동 폭
$2.455
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
명칭
Atea Pharmaceuticals Inc
전화
(857) 284-8891
주소
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
6.00 | 470.86M | 351.37M | -158.35M | -132.03M | -1.9523 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 개시 | Evercore ISI | Outperform |
| 2020-11-24 | 개시 | JP Morgan | Overweight |
| 2020-11-24 | 개시 | Morgan Stanley | Overweight |
| 2020-11-24 | 개시 | William Blair | Outperform |
모두보기
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
AVIR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hedge Fund Bets: Can Atea Pharmaceuticals Inc stock double in the next yearEarnings Summary Report & Precise Buy Zone Identification - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ: AVIR) officer exercises options for 60,000 shares - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month HighHere's Why - MarketBeat
Atea Pharma presents data on compounds for hepatitis E - BioWorld MedTech
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI - GuruFocus
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript - Insider Monkey
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - AOL.com
AVIR PE Ratio & Valuation, Is AVIR Overvalued - Intellectia AI
Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026 - TipRanks
Can Atea Pharmaceuticals Inc stock double in the next year2025 Winners & Losers & Consistent Income Trade Ideas - baoquankhu1.vn
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Atea Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-03-05 - Seeking Alpha
Atea Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
AVIR: Phase III HCV trials near completion, HEV pipeline expanded, and cash runway extends through 2027 - TradingView
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss - Investing.com
AVIR: Phase 3 HCV trials near completion, with robust cash and new HEV candidate advancing - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Atea Pharmaceuticals : Q4 FY25 IR Slide Deck 3 5 26 FINAL - marketscreener.com
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
BRIEF-Atea Pharmaceuticals Q4 Basic EPS USD -0.57 - TradingView
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - Benzinga
Risk Off: Can Atea Pharmaceuticals Inc navigate macro headwinds2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
AVIR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - The Manila Times
Atea Pharmaceuticals to Host Fourth Quarter and Full Year - GlobeNewswire
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - Defense World
AVIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atea Pharmaceuticals presents preclinical results of AT-587 - marketscreener.com
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - GlobeNewswire
No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR - Defense World
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - AOL.com
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
Is Atea Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
AVIR Should I Buy - Intellectia AI
Published on: 2026-02-08 21:54:48 - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2%Time to Sell? - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% – Here’s What Happened - Defense World
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26% - AOL.com
Street Watch: Is Atea Pharmaceuticals Inc attractive for institutional investorsIndex Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Atea Pharmaceuticals Inc (AVIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):